Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 2013

View Archived Issues

Janssen and J&J announce research alliance with the Icahn School of Medicine

Seattle Genetics and Agensys set to develop additional antibody-drug conjugate

Information and data on numerous nivolumab clinical trials presented

Immune Design and Medicago collaborate on novel pandemic influenza vaccine development

Islet Sciences' chief scientific officer receives grant from JDRF

A novel anti-inflammatory fusion protein inhibits chronic inflammatory and neuropathic pain in vivo

Resverlogix reports topline data from the ASSURE trial

Soligenix completes phase I study of SGX-203 for pediatric Crohn's disease

[18F]-PR-04.MZ evaluated for dopamine transporter quantification in humans

Central venous thrombosis recurrence linked to JAK2 gene V617F mutation

EMA gives Provenge a positive opinion

Procysbi receives positive CHMP recommendation

FDA approves first nonhormonal therapy for menopause-related vasomotor symptoms

Researchers in Portugal patent novel agents for the treatment of tuberculosis

Janssen Pharmaceutica divulges new stearoyl-CoA desaturase inhibitors

FDA approves Latuda as monotherapy and adjunctive therapy for bipolar depression

Fresenius divests biotech business

Bayer patents new Mnk1 inhibitors

Janssen presents bioequivalence results for darunavir/cobicistat fixed-drug combination

AV-0113 receives FDA orphan drug designation

German and Saudi researchers present novel vaccines

NeuroMax signs license agreement with Aquilus Pharmaceuticals for AQU-005

New histamine H3 receptor antagonists disclosed by Taisho Pharmaceutical

Emergent BioSolutions receives approval for BioThrax in Germany

EMA approves positive opinion on Omeros' pediatric investigation plan

FDA accepts NDA filing for cangrelor

Novartis seeks approval of ELC-200 in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...